Comparison of four distinct detection platforms using multiple ligand binding assay formats.

Several detection platforms are available for ligand binding assays (LBA), each claiming superiority in sensitivity and dynamic range. However, little information exists in the literature directly comparing the various LBA platforms for quantitation. We have tested four common platforms to evaluate and compare the interchangeability of detection platforms by comparing sensitivity and dynamic range to a colorimetric LBA. The detection platforms compared are: colorimetric, chemiluminescence, time-resolved fluorescence (TRF) and electrochemiluminescence (ECL). Five different LBA protocols were tested with each of the detection endpoints. The assay protocols include the following ligand binding assay formats: direct binding, sandwich ELISA, competitive and cell based ELISA. We found that no detection platform consistently performed better than all the others and it was not possible to predict which platform would perform best for a given assay protocol. We also found surprising differences in assays (plate coating efficiency, low signal) which add to difficulty in choosing the best platform ad hoc. We propose here that in developing new assay protocols for detection of biotherapeutic agents, multiple detection platforms should be tested in order to forward the best assays possible and for the right reasons.

[1]  Peter J. Burke,et al.  Electrochemiluminescence as a tool for microscopy at the nanoscale , 2004, SPIE BiOS.

[2]  Sridhar Samineni,et al.  Optimization, Comparison, and Application of Colorimetric vs. Chemiluminescence Based Indirect Sandwich ELISA for Measurement of Human IL‐23 , 2006, Journal of immunoassay & immunochemistry.

[3]  K. HayGlass,et al.  Comparison of chemiluminescent assays and colorimetric ELISAs for quantification of murine IL-12, human IL-4 and murine IL-4: chemiluminescent substrates provide markedly enhanced sensitivity. , 2001, Journal of immunological methods.

[4]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[5]  Alexander N. Cartwright Nanobiophotonics and Biomedical Applications , 2004 .

[6]  George V. Ludwig,et al.  Comparison of Dissociation-Enhanced Lanthanide Fluorescent Immunoassays to Enzyme-Linked Immunosorbent Assays for Detection of Staphylococcal Enterotoxin B, Yersinia pestis-Specific F1 Antigen, and Venezuelan Equine Encephalitis Virus , 2001, Clinical Diagnostic Laboratory Immunology.

[7]  Jennifer Yohrling,et al.  Ligand-binding assays: risk of using a platform supported by a single vendor. , 2009, Bioanalysis.

[8]  S R Merridew,et al.  Antigliadin antibody measurement by chemiluminescence ELISA in the diagnosis of coeliac disease. , 1995, Journal of clinical pathology.